Pfizer and BioNTech’s coronavirus vaccine may be effective in neutralizing rapidly spreading variants of SARS-CoV2 that have developed in the UK and South Africa, according to the findings of a preliminary laboratory study. The study conducted by Pfizer (PFE) and the University of Texas Medical branch suggests that the US drugmaker’s mRNA-based COVID-19 vaccine, BNT162b2, could be used in the neutralization of the virus with the co-called N501Y mutant, found in two rapidly rapidly variants of SARS-CoV-2.